Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

TIGIT and CD 96: new checkpoint receptor targets for cancer immunotherapy

1 Mar 2017

Abstract excerpt

While therapies targeting the co-inhibitory or immune checkpoint receptors PD-1 and CTLA-4 have shown remarkable success in many cancers, not all patients benefit from these therapies. This has catalyzed enormous interest in the targeting of other immune checkpoint receptors. In this regard, TIGIT and CD96 have recently entered the limelight as novel immune checkpoint receptor targets. TIGIT and CD96 together...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Immune Cell Function and Interaction
Share to Immunotherapy and Immune Responses

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 28258695
DOI: 10.1111/imr.12518

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

TIGIT and CD 96: new checkpoint receptor targets for cancer immunotherapyPMID 28258695Read ↗

CD8+T cells expressing both PD-1 and TIGIT but not CD226 are dysfunctional in acute myeloid leukemia (AML) patients.Semantic proximity Read ↗

Negative immune checkpoints on T lymphocytes and their relevance to cancer immunotherapySemantic proximity Read ↗

Targeting Immune Checkpoints: Basic Signaling Pathways and Clinical Translation in Cancer TherapeuticsSemantic proximity Read ↗

Leveraging NKG2D Ligands in Immuno-OncologySemantic proximity Read ↗

Cytotoxic CD8+ T cells in cancer and cancer immunotherapySemantic proximity Read ↗

TIGIT and PD-L1 co-blockade promotes clonal expansion of multipotent, non-exhausted anti-tumor T cells by facilitating costimulationSemantic proximity Read ↗

Killer instincts: natural killer cells as multifactorial cancer immunotherapySemantic proximity Read ↗

Immunobiology and Conflicting Roles of the Human NKG2D Lymphocyte Receptor and Its Ligands in CancerSemantic proximity Read ↗

Immune checkpoint signaling and cancer immunotherapySemantic proximity Read ↗

Coinhibitory Pathways in Immunotherapy for CancerSemantic proximity Read ↗

PD-1, CTLA-4, LAG-3, and TIGIT: The roles of immune checkpoint receptors on the regulation of human NK cell phenotype and functionsSemantic proximity Read ↗

Co-Inhibitory Pathways and Their Importance in Immune RegulationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.